Service Utilization and Survival By Treatment Approach for Medicare Beneficiaries Diagnosed with Acute Myeloid Leukemia

Background: Acute myeloid leukemia (AML) requires timely access to treatment for best patient outcomes. Despite available treatment options, including chemotherapy or allogeneic hematopoietic cell transplantation (alloHCT), some older patients do not receive any active therapy, particularly those aged 65-74. Although previous studies have analyzed costs and resource use associated with AML, little is known about the use of specific services by treatment approach, like HLA typing, palliative or hospice care, clinical trial participation, or cancellation of alloHCT within the first year of AML diagnosis. This study aimed to identify and analyze service utilization of specified services for patients age 65-74 diagnosed with AML on Medicare, by treatment approach (chemotherapy alone [chemo], chemotherapy and alloHCT [alloHCT], and no chemotherapy or alloHCT [no chemo]).